Compare
Pelthos Therapeutics Inc. vs Alpha Cognition Inc. vs Scilex Holding Co vs X4 Pharmaceuticals, Inc
| Latest fiscal year | Pelthos Therapeutics Inc. PTHS | Alpha Cognition Inc. ACOG | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | X4 Pharmaceuticals, Inc XFOR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $16.80M | $10.22M | $30.25M | $35.11M |
| Revenue growth (YoY) | n/a | n/a | -46.5% | n/m |
| Gross margin | 76.3% (computed) | 94.1% (computed) | 65.0% (computed) | 83.6% (computed) |
| Operating margin | -193.1% | -221.7% | n/m | -247.4% |
| Net margin | -257.9% | -202.2% | n/m | -225.6% |
| Net income | -$43.32M | -$20.67M | -$374.05M | -$79.20M |
| EPS (Diluted) | -$23.04 | -$1.18 | -$36.48 | -$1.87 |
| Operating cash flow | -$22.59M | -$20.38M | $3.82M | -$85.62M |
| Free cash flow | -$22.69M | -$20.67M | $3.68M | -$85.62M |
| Cash & equivalents | $17.97M | $66.05M | $4.96M | $217.05M |
| Total assets | $130.40M | $79.73M | $364.98M | $290.46M |
| Total liabilities | $91.52M | $17.20M | $576.73M | $104.17M |
| Shareholders' equity | $38.88M | $62.53M | -$207.78M | $186.29M |
| Return on year-end equity | -111.4% | -33.1% | n/a | -42.5% |
| Shares outstanding | 3.23M | 21.74M | 7.03M | 90.91M |
Revenue, most recent five fiscal years
| Fiscal year | Pelthos Therapeutics Inc. | Alpha Cognition Inc. | Scilex Holding Co | X4 Pharmaceuticals, Inc |
|---|---|---|---|---|
| Latest | $16.80M Ended 2025-12-31 | $10.22M Ended 2025-12-31 | n/a | $35.11M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | n/a | n/a | $2.56M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $0 Ended 2021-12-31 |